VA
VR Adviser Portfolio holdings
AUM
$1.33B
1-Year Return
6.92%
This Quarter Return
+19.93%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.33B
AUM Growth
+$159M
(+14%)
Cap. Flow
+$21.6M
Cap. Flow
% of AUM
1.62%
Top 10 Holdings %
Top 10 Hldgs %
74.55%
Holding
40
New
3
Increased
5
Reduced
6
Closed
9
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$34.7M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$32.2M |
| 3 |
CytomX Therapeutics
CTMX
|
$31.7M |
| 4 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$21.9M |
| 5 |
Savara
SVRA
|
$12.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$37.5M |
| 2 |
Cidara Therapeutics
CDTX
|
$20.1M |
| 3 |
Pharvaris
PHVS
|
$18.7M |
| 4 |
Dianthus Therapeutics
DNTH
|
$13.9M |
| 5 |
Solid Biosciences
SLDB
|
$9.18M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEPN
26
Septerna, Inc. Common Stock
SEPN
$643M
| $5.71M | 0.43% |
+540,453
| New | +$5.71M |
|
27
Surrozen
SRZN
$105M
| $5.66M | 0.42% |
632,931
| – | – |
|
28
Zura Bio
ZURA
$143M
| $4.86M | 0.36% |
4,631,216
-391,950
| -8% | -$412K |
|
|
ARTV
29
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$88.2M
| $2.43M | 0.18% |
1,609,569
| – | – |
|
30
CASI Pharmaceuticals
CASI
$36.3M
| $1.16M | 0.09% |
987,259
| – | – |
|
31
Tenax Therapeutics
TENX
$27.4M
| $568K | 0.04% |
98,564
-109,769
| -53% | -$632K |
|
32
Applied Therapeutics
APLT
$68.2M
| – | – |
-5,567,709
| Closed | -$2.72M |
|
33
4D Molecular Therapeutics
FDMT
$340M
| – | – |
-677,600
| Closed | -$2.19M |
|
34
Century Therapeutics
IPSC
$43.6M
| – | – |
-2,498,069
| Closed | -$1.19M |
|
35
Mersana Therapeutics
MRSN
$34M
| – | – |
-142,973
| Closed | -$1.23M |
|
|
36
Praxis Precision Medicines
PRAX
$986M
| – | – |
-989,985
| Closed | -$37.5M |
|
|
37
Solid Biosciences
SLDB
$428M
| – | – |
-2,481,400
| Closed | -$9.18M |
|
38
Instil Bio
TIL
$213M
| – | – |
-33,177
| Closed | -$576K |
|
39
Tenaya Therapeutics
TNYA
$220M
| – | – |
-1,555,556
| Closed | -$887K |
|
40
Trevi Therapeutics
TRVI
$854M
| – | – |
-615,506
| Closed | -$3.87M |
|